By Counterforce Health Team in Keytruda (pembrolizumab) —

How to Get Keytruda (pembrolizumab) Covered by Aetna (CVS Health) in Michigan: Complete Appeals Guide with Forms and Timelines

Answer Box: Getting Keytruda Covered by Aetna (CVS Health) in Michigan

Keytruda (pembrolizumab) requires prior authorization from Aetna (CVS Health) for all indications. Submit PA documentation including pathology reports with PD-L1 CPS or MSI-H/dMMR biomarkers, staging, and prior therapy failures via your oncologist. If denied, you have 180 days to appeal internally, then 127 days to file external review with Michigan DIFS. Start by gathering your denial letter, biomarker results, and treatment history—then call Aetna's PA line at 1-888-267-3277.

Table of Contents

  1. Understanding Your Denial Letter
  2. Keytruda Prior Authorization Requirements
  3. Common Denial Reasons and Quick Fixes
  4. Step-by-Step Appeals Process
  5. Peer-to-Peer Review Strategy
  6. Michigan External Review Process
  7. Appeal Templates and Scripts
  8. Cost Assistance Options
  9. When to Escalate
  10. FAQ

Understanding Your Denial Letter

When Aetna (CVS Health) denies Keytruda coverage, your denial letter will include specific reason codes. The most common reasons for Keytruda denials include:

  • Missing biomarker testing (PD-L1 CPS, MSI-H/dMMR, TMB-H)
  • Incomplete staging documentation
  • Step therapy requirements not met
  • Off-label use without medical necessity
  • Quantity limit exceeded

Look for your appeal deadline in the letter—you typically have 180 days from the denial date to file an internal appeal with Aetna (CVS Health).

Keytruda Prior Authorization Requirements

Aetna requires prior authorization for Keytruda across all plan types. Here's what you need:

Coverage at a Glance

Requirement What It Means Where to Find It
Prior Authorization Required for all indications 2024 Precert List
Biomarker Testing PD-L1 CPS ≥1, MSI-H/dMMR, or TMB-H ≥10 FDA-approved companion diagnostics
Step Therapy May apply for NSCLC (Medicare Part B) Plan-specific formulary
Site of Care Outpatient preferred over hospital Clinical Policy Bulletin #966

Essential Documentation

Your oncologist must submit:

  • Pathology report confirming cancer diagnosis with ICD-10 codes
  • Biomarker results from FDA-approved tests (PD-L1 CPS, MSI-H/dMMR, TMB-H)
  • Complete staging (imaging within 3 months)
  • Prior therapy history with dates, responses, and reasons for discontinuation
  • Performance status (ECOG ≤2 or Karnofsky ≥60%)
  • Treatment plan with dosing schedule

Common Denial Reasons and Quick Fixes

Denial Reason How to Fix Required Documents
Missing PD-L1 testing Submit companion diagnostic results Lab report with CPS score
Wrong line of therapy Document prior failures/intolerance Treatment timeline with outcomes
Non-formulary status File formulary exception Medical necessity letter
Step therapy Prove preferred drugs failed/contraindicated Chart notes, adverse event reports
Experimental/investigational Cite FDA approval and NCCN guidelines FDA label, NCCN pages

Step-by-Step Appeals Process

Level 1: Internal Appeal (First 180 Days)

  1. Gather documents within 30 days of denial
    • Original denial letter
    • Updated biomarker testing
    • Peer-reviewed literature supporting use
    • Medical necessity letter from oncologist
  2. Submit appeal via:
    • Aetna provider portal
    • Fax: 1-888-267-3277
    • Mail to address on denial letter
  3. Timeline: 30 days for standard review, 72 hours for expedited (urgent medical need)

Level 2: Second Internal Appeal

If your first appeal fails, you can request a second internal review within 60 days. This involves a different medical reviewer and may include a peer-to-peer discussion.

Peer-to-Peer Review Strategy

Aetna offers peer-to-peer reviews where your oncologist can discuss the case directly with an Aetna medical director.

How to Request

  • Call: 1-833-491-1090 (specialty line)
  • Timeline: Within 14 days of denial
  • Preparation: Have patient chart, biomarker results, and treatment rationale ready

Physician Talking Points

  • Emphasize FDA-approved indication match
  • Document failed prior therapies with specific dates
  • Reference NCCN guideline recommendations
  • Highlight patient-specific contraindications to alternatives
From Our Advocates: We've seen peer-to-peer calls succeed when oncologists prepare a 2-3 sentence summary of why Keytruda is medically necessary for this specific patient, backed by biomarker results and prior treatment failures. Keep the discussion clinical and reference the plan's own published criteria.

Michigan External Review Process

If Aetna's internal appeals fail, Michigan offers robust external review rights through the Department of Insurance and Financial Services (DIFS).

Key Details for Michigan

  • Filing deadline: 127 days from final internal denial
  • Cost: Free to patients
  • Timeline: 72 hours for expedited cases, up to 60 days for standard
  • Decision: Binding on Aetna

How to File

  1. Online: DIFS External Review Form
  2. Phone: 877-999-6442 for assistance
  3. Required documents:
    • Aetna's final denial letter
    • Medical records supporting necessity
    • Treating provider certification (if experimental/investigational denial)

The Michigan DIFS will assign an Independent Review Organization (IRO) with oncology expertise to evaluate your case impartially.

Appeal Templates and Scripts

Medical Necessity Letter Template

[Date]
Aetna Medical Review
Re: [Patient Name], Policy #[Number]

Dear Medical Director,

I am writing to appeal your denial of Keytruda (pembrolizumab) for my patient with [diagnosis]. This treatment meets FDA-approved indications and is medically necessary based on:

1. **Confirmed biomarker status**: [PD-L1 CPS score/MSI-H status]
2. **Prior therapy failures**: [List with dates and reasons for discontinuation]
3. **Clinical guidelines support**: NCCN Category [1/2A] recommendation
4. **No suitable alternatives**: [Explain contraindications to other options]

Attached documentation includes pathology reports, biomarker testing, and treatment timeline. I am available for peer-to-peer discussion.

Sincerely,
[Physician signature]

Patient Phone Script

When calling Aetna member services:

"I received a denial for Keytruda for my cancer treatment. I'd like to start the appeals process and request a peer-to-peer review between my oncologist and your medical director. Can you please provide the appeals address and peer-to-peer phone number?"

Cost Assistance Options

While appealing, explore these financial assistance programs:

  • Merck Access Program: Income-based assistance for eligible patients
  • Copay assistance: Up to $25,000 annually for commercially insured patients
  • State programs: Michigan residents may qualify for additional support through local cancer organizations

Counterforce Health helps patients navigate these complex approval processes by analyzing denial letters, identifying the specific basis for denial, and crafting targeted appeals that address payer requirements with evidence-backed rebuttals.

When to Escalate

File a Complaint with Michigan DIFS

If you experience delays or procedural violations:

  • Phone: 877-999-6442
  • Online: File complaint through DIFS website
  • Documents to include: Timeline of communications, denial letters, appeal submissions

Contact Your State Representatives

Michigan has strong patient advocacy laws. Your state legislators can sometimes expedite reviews for urgent medical needs.

FAQ

How long does Aetna prior authorization take for Keytruda in Michigan? Standard PA decisions take 30-45 days. Expedited reviews for urgent cases are completed within 72 hours.

What if Keytruda is non-formulary on my Aetna plan? You can request a formulary exception by documenting medical necessity and why preferred alternatives are inappropriate.

Can I get an expedited appeal if my cancer is progressing? Yes. Michigan allows expedited external reviews within 72 hours if delay would seriously jeopardize your health. Your doctor must provide supporting documentation.

Does step therapy apply to all Keytruda indications? Step therapy primarily applies to Medicare Part B coverage for NSCLC, where preferred PD-1/PD-L1 inhibitors must be tried first unless contraindicated.

What biomarker testing is required for Keytruda coverage? Requirements vary by cancer type: PD-L1 CPS ≥1 for many indications, MSI-H/dMMR for certain solid tumors, and TMB-H ≥10 mutations/Mb for others. Use FDA-approved companion diagnostics.

How much does Keytruda cost without insurance? Merck lists approximately $23,591 per 6-week dose, with total costs varying by weight-based dosing and treatment duration.

This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for specific coverage decisions.

Sources & Further Reading

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.